Pablo Bonangelino

Pablo Bonangelino

Auto-generated profile, based on publicly available information

Pablo Bonangelino

CDER, FDA, Silver Spring, USA

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 April 2023 in International Journal of Surgery
Verified
Journal Article
Open access
MNMarc J. Beng Nieuwenhuijse
Marc J. Beng Nieuwenhuijse
PRPer-Henrik Randsborg
Per-Henrik Randsborg
JHJensen H. Hyde
Jensen H. Hyde
WXWenna Xi
Wenna Xi
PFPatricia Franklin
Patricia Franklin
ASArt Sedrakyan
Art Sedrakyan
Background: Objective performance criteria (OPC) is a novel method to provide minimum performance standards and improve the regulated introduction of original or incremental device innovations in order to prevent patients from being exposed to potentially inferior designs whilst allowing timely access to improvements. We developed 2-year safety and effectiveness OPC for total hip and knee replacement (THR and TKR). Methods: Analyses of large databases were conducted using various data sources: a systematic literature review; a direct data analysis from The Functional Outcomes Research for Comparative Effectiveness in Total Joint Replacement and Quality Improvement Registry (FORCE-TJR) and the Kaiser Permanente Implant Registry (KPIR); and claims data analyses from longitudinal discharge data in New York and California states. The literature review included U.S. patients (≥18 years) who received THR or TKR for primary end-stage osteoarthritis and prospectively collected data on patient-reported outcome measures (PROMs) from at least 100 subjects and/or 2-year implant survival for at least 250 implants. Random effects models were used for meta-analysis. Results: Data were available from a total of 951 100 patients. After screening of 7979 abstracts, 294 studies underwent full-text review and 31 studies contributed to the evidence synthesis (333 995 implants). Direct data analysis of FORCE-TJR contributed 9223 joint replacement patients to the construction of OPC for effectiveness; KPIR contributed 262 044 patients for the construction of OPC for safety. Claims database analysis contributed 345 838 patients to the construction of safety OPC. OPC for safety were constructed for cumulative incidences of 2-year all-cause and septic revision (THR/TKR 2.0%/1.6% and 0.6%/0.7%), and OPC for effectiveness were constructed based on four disease-specific and three general health-related quality of life PROMs (HOOS/KOOS 87.1/80.6; HSS/KSS function 94.4/90.6; SF-12/SF-36, PCS 46.5/41.9, EQ-5D 0.88/0.84). Conclusion: This study is the first to construct a 2-year OPC for the safety and effectiveness of THR and TKR based on U.S. real-world data. Based on these OPC, potential benchmarks for (single-arm study) evaluation of new device innovations are suggested for a regulated and safe introduction to the (commercial) market.

22 January 2026 in Statistics in Biosciences
Verified
Journal Article
Closed access
PDF file
ADApu Chandra Das
Apu Chandra Das
YGYeongjin Gwon
Yeongjin Gwon
PBPablo Bonangelino
Pablo Bonangelino

4 October 2025 in Therapeutic Innovation & Regulatory Science
Verified
Journal Article
Closed access
PDF file
RCRoberto Crackel
Roberto Crackel
YJYuanyuan Ji
Yuanyuan Ji
YKYoonhee Kim
Yoonhee Kim
JTJames Travis
James Travis
WTWenda Tu
Wenda Tu
PBPablo Bonangelino
Pablo Bonangelino